Treatment of Oral Thrush with Fluconazole in Immunocompetent Patients

Primary Treatment Regimen

The Infectious Diseases Society of America (IDSA) recommends fluconazole 100-200 mg orally once daily for 7-14 days as the standard treatment for oropharyngeal candidiasis in immunocompetent adults, with strong evidence supporting its efficacy and safety 1
The IDSA guidelines provide a strong recommendation with high-quality evidence for this regimen 1

Fluconazole significantly enhances warfarin's anticoagulant effect, requiring close INR monitoring and likely dose reduction of warfarin, as recommended by the Centers for Disease Control and Prevention (CDC) 2, 3
Fluconazole increases phenytoin levels, necessitating phenytoin level monitoring and potential dose adjustment, according to the CDC 2, 3
Additional interactions to consider include oral hypoglycemic agents, calcium channel antagonists, and cyclosporine, as noted by the CDC 2, 3

Uncontrolled diabetes is a risk factor for recurrent candidiasis and may require longer treatment duration (10-14 days), as recommended by the CDC 2
Fluconazole can potentiate oral hypoglycemic agents, requiring blood glucose monitoring, according to the CDC 2, 3

Itraconazole oral solution 200 mg daily for 7-14 days is an alternative regimen for patients who cannot use fluconazole due to drug interactions, as recommended by the IDSA 1, 4

Itraconazole solution 200 mg daily is the preferred second-line agent for treatment failure, as recommended by the IDSA 1, 5
Posaconazole suspension 400 mg twice daily for 3 days, then 400 mg daily achieves 75% efficacy in refractory cases, according to the IDSA 5

Disinfection of dentures is mandatory in addition to antifungal therapy, as recommended by the IDSA 1, 5, 6

Fluconazole 100 mg three times weekly is recommended for patients with recurrent infections (≥4 episodes annually), as recommended by the IDSA 1, 3, 5

The CDC recommends avoiding the use of ketoconazole due to hepatotoxicity risk and extensive drug interactions 2, 4, 7
The IDSA recommends not using topical agents alone for moderate-to-severe disease, as systemic therapy is required 1, 4

Clinical response should be evident within 3-5 days; if not, obtain fungal cultures, as recommended by the IDSA 5
Continue treatment for at least 48 hours after symptom resolution, according to the IDSA 5
Monitor INR closely if on warfarin, as recommended by the CDC 2, 3
Monitor phenytoin levels if on phenytoin, according to the CDC 2, 3
Monitor blood glucose if diabetic and on oral hypoglycemics, as recommended by the CDC 2, 3